Anti-Hu PODXL PE

Anti-Hu PODXL PE
Regulatory status
RUO
Antigen
PODXL
Clone
PcMab-47
Format
PE
Reactivity
Human
Application
Excitation laser
blue (488 nm)
Variant
0.1 mg
1P-899-C100
In stock
242.00 USD
Variant
0.1 mg
1P-899-C100
In stock
242.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody PcMab-47 recognizes a glycosylation-dependent epitope (aa 207-210) on human PODXL, a highly glycosylated transmembrane glycoprotein expressed above all in many types of cancer tissues, and on embryonic stem cells.
Application
Application details
Flow cytometry: Recommended dilution: 1-5 μg/ml.
Reactivity
Human
Immunogen
recombinant PODXL ectodomain
Concentration
0.1 mg/ml
Preparation
Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
PCLP-1, Gp200, podocalyxin like
Antigen description
PODXL is a highly glycosylated sialomucin, which is expressed in many types of tumors, as well as it is a well known marker of embryonic stem cells. Overexpression of PODXL is an independent predictor of cancer progression, metastasis, and poor outcome. PODXL promotes tumor growts and invasiveness, and is a potential target for antibody therapy.
Entrez Gene ID 5420
UniProt ID O00592
1P-899_FC_Histogram
Separation of HeLa cells stained using anti-human PODXL (PcMab-47) PE antibody (concentration in sample 5 μg/m, red-filled) from HeLa cells stained using mouse IgG1 isotype control (MOPC-21) PE antibody (concentration in sample 5 μg/ml, same as PODXL PE concentration, black-dashed) in flow cytometry analysis (surface staining).

Product specific references:

Schulten HJ, Hussein D: Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas. PLoS One 2019 May 13;14(5):e0215452.
PubMed
Itai S, Yamada S, Kaneko MK, Kato Y: Determination of critical epitope of PcMab-47 against human podocalyxin. Biochem Biophys Rep. 2018 Apr 24;14:78-82.
PubMed
Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y: PcMab-47: Novel antihuman podocalyxin monoclonal antibody for immunohistochemistry. Monoclon Antib Immunodiagn Immunother. 2017 Apr;36(2):50-56.
PubMed
Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y: Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget 2018 Apr 27;9(32):22480-22497.
PubMed
Kaneko MK, Ohishi T, Kawada M, Kato Y: A cancer-specific anti-podocalyxin monoclonal antibody (60-mG 2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. Biochem Biophys Rep. 2020 Oct 10;24:100826.
PubMed
Variant
0.1 mg
1P-899-C100
In stock
242.00 USD
Variant
0.1 mg
1P-899-C100
In stock
242.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
198.00 USD